Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179881 · ClinicalTrials.gov registry record · Phase 2
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
A Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 6
- Study locations
NCT00179881 is a Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 47 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT00179881, a Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 6
- Study locations
Study Summary
Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the process of new blood vessel formation). If a tumor does not have blood vessels providing oxygen and nutrients, it will not be able to grow. This research will look at how combining the effects of thalidomide (preventing tumor growth) with the tumor killing effect of carboplatin effects the long-term outlook for patients with these tumors. This study will try to find out how well Thalomid™ and carboplatin combined with radiation therapy works in treating children newly diagnosed with brain stem glioma. This study will look at how well Thalomid ™ and carboplatin work in patients with recurrent brain stem glioma. This study will also look at any side effects of these treatments.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Thalomid
- PROCEDURE External Beam Radiation Therapy
Study Locations (6)
Minnesota
- Children's Hospitals and Clinics - Minneapolis
- Children's Hospitals and Clinics - Saint Paul
Arizona
- Phoenix Children's Hospital - Phoenix
Illinois
- Children's Memorial Hospital - Chicago
Missouri
- Washington University Medical Center - St Louis
Ohio
- Children's Medical Center - Dayton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 1999-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179881
The ClinicalTrials.gov registry entry for NCT00179881 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Stem Neoplasms, Primary appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT00179881 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Minnesota, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT00179881 about?
NCT00179881 is a clinical study titled "Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma". Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the proces...
What is the current status of trial NCT00179881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 1999-12. Estimated completion is 2007-04.
What conditions does trial NCT00179881 study?
This clinical trial studies the following conditions: Brain Stem Neoplasms, Primary, Neoplasms, Brain Stem.
What interventions are being tested in trial NCT00179881?
The interventions under investigation include: Carboplatin (DRUG), Thalomid (DRUG), External Beam Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00179881?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179881 being conducted?
This trial has 6 study locations across Arizona, Illinois, Minnesota, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.